Analytical Data
-
Gene name
AGER
- Application
-
Alternative Names
Receptor for advanced glycosylation end products
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15109
-
Expression Region
23-342aa
-
Molecular Weight
38 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AGER, or Advanced Glycation End-products Receptor, is a receptor that plays a significant role in various pathological processes, particularly in the context of diabetes, Alzheimer's disease, and other age-related disorders. The research background on AGER focuses on its involvement in the molecular mechanisms underlying chronic inflammation, oxidative stress, and tissue remodeling associated with these diseases. Elevated levels of advanced glycation end-products, which result from the non-enzymatic glycation of proteins and lipids, activate AGER signaling pathways. This activation has been implicated in promoting inflammatory responses and contributing to cellular dysfunction and apoptosis. Researchers have been investigating the potential of AGER as a therapeutic target for modulating these pathogenic processes. Studies have shown that inhibiting AGER or its ligands can reduce inflammation and improve metabolic outcomes in animal models. Furthermore, AGER's role in cognitive decline and neurodegenerative diseases has garnered attention, as its activation can exacerbateβ-amyloid plaque formation and tau phosphorylation, two hallmarks of Alzheimer's disease. The ongoing research aims to better understand AGER's diverse functions, explore its interactions with other signaling pathways, and develop AGER-based therapeutic approaches that could provide new strategies for treating age-related diseases and improving overall healthspan.
